5-(4-丁氧基-3-氯苯基)-N-[[2-(4-吗啉)-3-吡啶基]甲基]-3-吡啶甲酰胺 | 1266212-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-(4-丁氧基-3-氯苯基)-N-[[2-(4-吗啉)-3-吡啶基]甲基]-3-吡啶甲酰胺
• 英文名称: 5-(4-Butoxy-3-chlorophenyl)-N-[[2-(4-morpholinyl)-3-pyridinyl]methyl]-3-pyridinecarboxamide
• 英文别名: 5-(4-butoxy-3-chlorophenyl)-N-[(2-morpholin-4-ylpyridin-3-yl)methyl]pyridine-3-carboxamide
• CAS: 1266212-81-0
• 化学式: C₂₆H₂₉ClN₄O₃
• 分子量: 481.0
• InChiKey: JPJGFWKHSMUKFO-UHFFFAOYSA-N

物化性质

• 沸点：
  711.5±60.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜：≥5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  76.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US11221329B2

  公开（公告）日：2022-01-11

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

  本发明提供了用于治疗和/或减轻神经或神经发育疾病或紊乱症状的方法，该疾病或紊乱的特征是某些离子通道的异位表达，特别是 Nav1.8 亚型 SCN10a 钠通道或 KCNQ1 钾通道在中枢神经系统（CNS）神经细胞中的异位表达。8亚型SCN10a钠通道或KCNQ1钾通道的方法，该方法通过向有需要的受试者施用一种或两种这些离子通道的拮抗剂，特别是SCN10a的拮抗剂，以阻断、减少或抑制异常的中枢神经系统（CNS）离子通道、或抑制异常的中枢神经系统神经元离子通道表达和/或活性，使与神经系统和神经发育疾病或紊乱相关的行为和认知缺陷正常化，从而治疗和/或减轻神经系统或神经发育疾病或紊乱的症状。可通过所述方法治疗的此类疾病或紊乱的例子包括皮特-霍普金斯综合征（PTHS）、自闭症、自闭症谱系障碍、精神分裂症、18q 综合征等。
• PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8
  申请人：Lieber Institute, Inc.

  公开号：EP3820866A1

  公开（公告）日：2021-05-19
• Treatment of Neurological and Neurodevelopmental Diseases and Disorders Associated with Aberrant Ion Channel Expression and Activity
  申请人：LIEBER INSTITUTE FOR BRAIN DEVELOPMENT

  公开号：US20180328915A1

  公开（公告）日：2018-11-15

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.
• [EN] TREATMENT OF NEUROLOGICAL AND NEURODEVELOPMENTAL DISEASES AND DISORDERS ASSOCIATED WITH ABERRANT ION CHANNEL EXPRESSION AND ACTIVITY<br/>[FR] TRAITEMENT DE MALADIES ET DE TROUBLES NEUROLOGIQUES ET NEURDÉVELOPPEMENTAUX ASSOCIÉS À UNE EXPRESSION ET À UNE ACTIVITÉ ABERRANTE DES CANAUX IONIQUES
  申请人：LIEBER INST FOR BRAIN DEV

  公开号：WO2017075222A1

  公开（公告）日：2017-05-04

  Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.